Reprint

Personalized Medicine in the Field of Inflammatory Skin Disorders

Edited by
March 2022
262 pages
  • ISBN978-3-0365-3574-6 (Hardback)
  • ISBN978-3-0365-3573-9 (PDF)

This book is a reprint of the Special Issue Personalized Medicine in the Field of Inflammatory Skin Disorders that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

Skin inflammation is associated with a wide range of conditions which represent major health issues worldwide. Skin and mucosal surfaces represent the primary interface between the human body and the environment, susceptible to numerous factors whose action results in diseases produced by chemical substances, mechanical trauma, microbial agents, radiation, etc. Inflammation, a complex network of interactions between soluble molecules and cells, represents the main modality of the skin’s response to injuries. Numerous studies have revealed close links between chronic inflammation, oxidative stress, and carcinogenesis. Chronic inflammation induces the activation of various cell types and an increase in the production of reactive oxygen species, promoting the initiation of a malignant process. Identifying specific biomarkers is essential for understanding molecular mechanisms and developing therapies appropriate to the patient’s characteristics.Personalized medicine is an emerging field of medicine that has the potential to predict which therapy will be safe and efficacious for specific patients using an individual’s genetic profile to guide decisions regarding the diagnosis, treatment, as well as prevention of disease. This book gathers articles that present recent advancements in research involving the mechanisms that underlie the development of inflammatory skin disorders, skin and mucosal inflammation in general.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
sea-buckthorn seed oil; long-chain fatty acids; skin dysplastic keratinocytes; UVA; CD36; SR-B2; atopic dermatitis; eczema; JAK inhibitors; systematic review; meta-analysis; evidence-based medicine; immune-mediated skin diseases; target therapy; skin conditions and systemic inflammatory diseases; systemic sclerosis; biomarker; calumenin; S100A6; cytohesin 2; cannabinoids; inflammation; gut-lung-skin barrier; signaling pathways; inflammatory biomarkers; psoriasis vulgaris; prevalence; comorbidities; risk factors; systemic lupus erythematous; lupus nephritis; lipid peroxidation; DNA oxidation; oxidized proteins; carbohydrate oxidation; antioxidative stress strategies; biomarkers; IgY; psoriatic dermatitis; imiquimod; inflammation; C57 BL/6 mice; alginate; biomaterial; dressing; fibers; hydrogel; nanofibers; commercially available; wound care; wound healing; cutaneous melanoma; epigenetic regulation; inflammation; drug resistance; biomarkers; therapeutic targets; epigenetic therapy; immune response; immune response; inflammation; Sutton nevi; halo nevi; skin tumor; psoriasis; proteome analysis; estrogen; menopause; cSCC; AK; sialylation; sialyltransferase; sialidase; COVID-19; pyoderma gangrenosum; immunosuppression; cyclosporine; corticosteroids; autoinflammatory disease; androgenic alopecia; clinical trial; hair density; inflammation; meta-analysis; platelet-rich plasma; n/a